This Webinar provides perspectives on the evolving role of Digital Opinion Leaders in medical education and shares approaches for identifying, monitoring and engaging them in a compliant manor with relevant examples.
Part 2 of this series will discuss statistical analysis in clinical trials including null/alternative hypotheses; statistical assumptions (type I error, significance level, type II error, statistical power); hypothesis testing; Statistics used in RCTs, including type of outcome measures, analysis of time-to-event variables (plotting and interpretation of Kaplan-Meier curves).
Early Access includes a variety of programs by which pharmaceutical companies make investigational therapies available to patients with life-threatening diseases. These patients have either exhausted available treatments or have no approved options. This presentation will review the processes and procedures to consider in the implementation of an Early Access Program and explore the opportunities and challenges posed therein.
Understand the numerous ways in which partnership with patients can impact the development and commercialization of medicines; the current “patient centric” landscape in pharmaceutical drug development; recent findings related to the value of patient-centric trial design, and innovative approaches to engaging with patients across the study continuum.
MSLs are becoming more important and playing key roles across the lifecycle in partnership with many others who play important roles. We will describe the landscape, drivers, and opportunities for engaging with customers across the lifecycle and how we socialize learnings across the organization.
Ensure understanding of the basic components and processes involved in the development of a scientific communication platform (SCP); how to develop and/or update an SCP so that the scientific and value narratives are integrated; learn how to train and implement an SCP across functional teams; glean insights into tailoring a global SCP to a regional SCP
Part 1 of this series will: define terminologies in statistics; explain different types of data (quantitative vs. qualitative); describe different ways in presenting summary data (such as proportions, means, medians, range and standard deviation); explain 95% confidence intervals; discuss bivariate analyses and appropriate statistical testing for quantitative and qualitative variables
Health technology and value assessment can be conducted using a variety of methods. Dr. Malone will provide an overview of those methods and an introduction on how to interpret the results from cost-effectiveness studies. This webinar will also discuss issues with defining value for health technologies, especially pharmaceuticals.
This Webinar explores: the role of Medical Affairs in guiding ethical decisions internally and externally; the impact of Medical Affairs beyond its remit; the importance of sharing best practices for the role of Medical Affairs in strategic brand planning, and the ethics and compliance considerations for Medical Affairs plans.
In this webinar, we explore two scenarios that can open Medical Affairs up to censure. Scenario one explores participation of commercial team members in Medical Advisory Boards and scenario two looks at the implications of a commercial team member requesting a medical team member to participate in a thought leader meeting.